MK-5684 (OTX-2002)

About Lantheus Holdings

Lantheus Holdings is a commercial leader in the radiopharmaceutical space, built on a vertically integrated model spanning discovery through global sales. Its strategy is anchored by the commercial success of PYLARIFY®, a leading PSMA PET imaging agent for prostate cancer, and DEFINITY®, an established ultrasound contrast agent. The company is advancing a deep pipeline of approximately 40 programs, targeting expansion in radiopharmaceutical oncology and diagnostics, while leveraging its robust manufacturing and commercial infrastructure to drive growth. With a market cap of ~$4.8B, Lantheus is positioned as a key consolidator and innovator in the high-growth targeted radiopharmaceutical sector.

Therapeutic Areas

Other mCRPC Drugs